212 related articles for article (PubMed ID: 26800997)
1. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Hayashi K; Akiho H; Nakashima Y; Haruma K
J Gastroenterol; 2016 Sep; 51(9):874-82. PubMed ID: 26800997
[TBL] [Abstract][Full Text] [Related]
2. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
[TBL] [Abstract][Full Text] [Related]
3. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
[TBL] [Abstract][Full Text] [Related]
4. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
[TBL] [Abstract][Full Text] [Related]
6. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
Qi Q; Zhang Y; Chen F; Zuo X; Li Y
BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
[TBL] [Abstract][Full Text] [Related]
8. Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.
Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
Biopsychosoc Med; 2017; 11():8. PubMed ID: 28331539
[TBL] [Abstract][Full Text] [Related]
9. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
Shiotani A; Kusunoki H; Ishii M; Imamura H; Manabe N; Kamada T; Hata J; Merchant JL; Haruma K
Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.
Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
Biopsychosoc Med; 2017; 11():7. PubMed ID: 28293280
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.
Chiba T; Yamamoto K; Sato S; Suzuki K
Clin Exp Gastroenterol; 2013; 6():123-8. PubMed ID: 23922505
[TBL] [Abstract][Full Text] [Related]
14. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
[TBL] [Abstract][Full Text] [Related]
15. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
16. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Min YW; Rhee PL
Therap Adv Gastroenterol; 2015 May; 8(3):136-42. PubMed ID: 25949526
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
Tomita T; Fukui H; Morishita D; Mori S; Oshima T; Shinzaki S; Miwa H
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498457
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
20. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
